Digital Pharma Lab
Contact
HAS transparency dossier: SMR, ASMR, contents, steps and common mistakes

HAS transparency dossier: SMR, ASMR, contents, steps and common mistakes

How the French Transparency Committee assesses a medicine, what SMR and ASMR mean, and how to prepare a robust dossier, step by step.

November 18, 2026 · Digital Pharma Lab

The transparency dossier is the assessment dossier a pharmaceutical company files with the French National Authority for Health (HAS) when it applies to the ministers for a medicine to be included in reimbursement. The Transparency Committee assesses two things in it: the Actual Clinical Benefit (SMR), which determines whether the medicine is covered, and the Clinical Added Value (ASMR), which weighs on the price negotiation. A robust dossier is built early, around a single question: what does this medicine add compared with existing treatments?

Up to date as of 18 November 2026.

What is the Transparency Committee?

The Transparency Committee (CT) is a specialised committee of the French National Authority for Health. It issues a scientific opinion on medicines for which the company requests inclusion on the list of medicines reimbursable to insured persons, or on the list of medicines approved for use by public bodies, mainly hospitals.

Its opinion is not a decision. It informs three bodies: the ministers responsible for health and social security, to whom the application for inclusion is addressed and who decide on inclusion by order; the National Union of Health Insurance Funds (UNCAM), which sets the reimbursement rate; and the Economic Committee for Health Products (CEPS), which negotiates the price with the company. The procedure is laid down in the French Social Security Code, in articles R.163-2 to R.163-21, including R.163-8 for the application and R.163-15 to R.163-21 for the committee.

The CT also reviews applications to renew an inclusion, indication extensions, and the re-assessments it decides itself, for example when new data or new treatments change a medicine's place in therapy: article R.163-21 allows it to re-assess a medicine on its own initiative or at the ministers' request.

What do SMR and ASMR measure?

The SMR answers the question: does this medicine deserve to be covered by national solidarity? It is assessed indication by indication. The French Social Security Code (article R.163-3) sets out its criteria: the medicine's efficacy and adverse effects, its place in the therapeutic strategy compared with other available therapies, the severity of the condition, the preventive, curative or symptomatic nature of the treatment, and its public health benefit.

The committee rates the SMR as major or important, moderate, low or insufficient. An insufficient SMR leads to an unfavourable opinion on inclusion. The other levels open the way to coverage, and the reimbursement rate depends on them.

The ASMR answers another question: does this medicine do better than what already exists? It is measured against clinically relevant comparators: according to the committee's doctrine, these may be an active medicine, a placebo, a medical device, a procedure or another non-drug therapy, at the same level of the therapeutic strategy and intended for the same patients. The committee selects one of the following five levels:

  1. ASMR I: major improvement;
  2. ASMR II: important improvement;
  3. ASMR III: moderate improvement;
  4. ASMR IV: minor improvement;
  5. ASMR V: no improvement, that is, no therapeutic progress.

The ASMR matters most for the price. Article R.163-5 of the French Social Security Code provides that a medicine which brings neither Clinical Added Value nor savings in the cost of drug treatment cannot be included. The ASMR is therefore a central element of the negotiation with the CEPS.

The CT opinion also specifies the populations concerned and an estimate of the number of patients, the clinically relevant comparators and, where relevant, the additional information and studies expected for a later re-assessment.

What does the dossier contain?

The HAS publishes the submission guide and the template of the Transparency Committee dossier on its website; filing is done online, on the SESAME platform. These documents change over time: it is worth rereading them before each submission. In practice, a dossier brings together:

  • the marketing authorisation documents, including the summary of product characteristics and, for a centralised European procedure, the European public assessment report of the European Medicines Agency;
  • the clinical studies supporting the application, with their efficacy and safety results, and the direct or indirect comparisons with the comparators;
  • an analysis of the medicine's place in the current therapeutic strategy in France;
  • a substantiated estimate of the target population;
  • the SMR and ASMR claimed, with their justification;
  • ongoing or planned studies, and the proposed follow-up commitments;
  • where applicable, the health-economic dossier intended for the Economic and Public Health Evaluation Committee (CEESP) (see our article on the efficiency opinion).

The quality of a dossier depends less on its volume than on its consistency: each claim must point to a specific piece of data, and each known limitation of the studies should be discussed rather than left unsaid.

How does the review unfold, step by step?

In broad terms, the process follows the steps set out in the French Social Security Code and specified by the HAS:

  1. the company sends its application for inclusion to the ministers and files its dossier with the HAS: under the centralised procedure, a pre-filing is possible as soon as the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion, and the formal filing follows the marketing authorisation;
  2. the HAS staff review the dossier, with support from experts where needed;
  3. the committee examines the dossier in session and adopts an opinion, which is sent to the company;
  4. the company may submit written observations or ask to be heard;
  5. the committee adopts the final opinion, which the HAS publishes on its website;
  6. the CEPS negotiates the price with the company, the UNCAM sets the reimbursement rate, and the inclusion order is published in the French Official Journal (Journal officiel).

European law frames the overall duration. Directive 89/105/EEC, known as the "transparency directive", sets at 180 days the time limit for a decision covering both the price and inclusion in reimbursement; a request for additional information suspends the time limit. Article R.163-9 of the French Social Security Code takes up this 180-day limit for the list of reimbursable medicines. The same code gives the company ten days after receiving the committee's opinion to ask to be heard or to submit written observations (article R.163-16); the hearing takes place within 45 days of the request.

Before filing, the HAS also offers early meetings, held by its staff, to discuss a medicine's development plan, often before phase III trials. This is a useful time to check that the chosen comparator and endpoints will meet the committee's expectations.

What are the most common mistakes?

The opinions published by the HAS show recurring pitfalls. Knowing them helps anticipate them from the design of the trials onwards.

  • A comparator that is not French practice. A trial against placebo when an active treatment exists, or against a treatment rarely used in France, leaves the committee without an answer to its central question.
  • A poorly justified indirect comparison. When there is no head-to-head trial, the method, the heterogeneity of the studies and their limitations must be set out in detail.
  • An ASMR claimed beyond the data. An overly ambitious claim weakens the credibility of the whole dossier; a well-argued request is generally stronger than a maximal one.
  • An endpoint of limited clinical relevance. A surrogate endpoint must be linked, with evidence, to a benefit for patients: survival, quality of life, clinical events.
  • A trial population far removed from French patients. Age, severity or prior treatments can limit the transferability of the results.
  • A poorly supported target population. Its estimate must rely on cited sources and a reproducible method.
  • Doctrine discovered too late. The committee publishes its doctrine and its opinions: reading those in the same therapeutic area, even before phase III, limits surprises.

How does the EU joint clinical assessment change the dossier?

Regulation (EU) 2021/2282 on health technology assessment has applied since 12 January 2025. It creates a joint clinical assessment (JCA) at EU level, rolled out in stages according to the date the marketing authorisation application is filed: first, medicines containing a new active substance intended to treat cancer and advanced therapy medicinal products; then orphan medicinal products whose application is filed from 13 January 2028; and from 13 January 2030 the other new medicines within the centralised procedure, excluding generics and biosimilars.

The joint assessment describes the relative effects of the medicine and the degree of certainty of those effects, based on research questions set in advance (population, intervention, comparators, outcomes). It decides neither price nor reimbursement, which remain national. The regulation does, however, require Member States to give due consideration to the joint report in their own assessments.

For a company, the consequence is practical: the European dossier and the French dossier should be consistent. The comparators and outcomes expected in France are worth identifying early, so that they appear in the European scoping.

Where to start?

A transparency dossier is worth preparing from phase II onwards: choice of comparator, endpoints, quality-of-life data, estimate of the target population. The earlier these choices are made, the less the final dossier depends on arguments built after the fact.

Three ways to get started: read the committee's doctrine and its recent opinions in the therapeutic area; write down, now, the SMR and ASMR claim you are aiming for and the data supporting it; anticipate what comes next, with the CEESP efficiency opinion if the product is subject to it, or early access if the medical need justifies it. AI can speed up part of this work, with safeguards: we describe them in what AI changes in market access.

This article provides general information; it does not replace regulatory advice tailored to your product. For support in preparing a dossier, discover our market access expertise.

Sources

Sources accessed on 18 November 2026.

Our expertise on this topic

  • Market Access

    Building robust access strategies, solid health-economic evaluations, and HAS dossiers that withstand scrutiny.